(19)
(11) EP 1 242 124 A1

(12)

(43) Date of publication:
25.09.2002 Bulletin 2002/39

(21) Application number: 00989347.0

(22) Date of filing: 21.12.2000
(51) International Patent Classification (IPC)7A61K 48/00, C12Q 1/70
(86) International application number:
PCT/US0034/724
(87) International publication number:
WO 0104/5748 (28.06.2001 Gazette 2001/26)
(84) Designated Contracting States:
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
Designated Extension States:
AL LT LV MK RO SI

(30) Priority: 22.12.1999 US 171542 P

(71) Applicant: Merck & Co., Inc.
Rahway,New Jersey 07065-0907 (US)

(72) Inventors:
  • SHIVER, John, W.
    Rahway, NJ 07065-0907 (US)
  • PERRY, Helen, C.
    Rahway, NJ 07065-0907 (US)
  • CASIMIRO, Danilo, R.
    Rahway, NJ 07065-0907 (US)
  • FU, Tong-Ming
    Rahway, NJ 07065-0907 (US)

(74) Representative: Thompson, John Dr. 
Merck & Co., Inc.European Patent DepartmentTerlings ParkEastwick Road
Harlow, Essex CM20 2QR
Harlow, Essex CM20 2QR (GB)

   


(54) POLYNUCLEOTIDE VACCINES EXPRESSING CODON OPTIMIZED HIV-1 POL AND MODIFIED HIV-1 POL